Detection of RASSF1A promoter hypermethylation in serum from gastric and colorectal adenocarcinoma patients  

作　　者：Yu-Cai Wang Zheng-HongYu Chang Liu Li-Zhi Xu Wen Yu Jia Lu Ren-Min Zhu Guo-Li Li Xin-Yi Xia Xiao-Wei Wei Hong-Zan Ji Heng Lu Yong Gao Wei-Min Gao Long-Bang Chen 

机构地区：[1]Department of Medical Oncology, Jinling Hospital, Nanjing 210002, Jiangsu Province, China [2]Medical School of Nanjing University, Nanjing 210093, Jiangsu Province, China [3]Department of Experimental Radiation Oncology, The University of Texas M.D. Anderson Cancer Center, The University of Texas Graduate School of Biomedical Sciences at Houston, Houston TX 77030, United States [4]Department of Molecular Pathology, The University of Texas M. D. Anderson Cancer Center, Houston TX 77030, United States [5]Department of Gastroenterology, Jinling Hospital, Nanjing 210002, Jiangsu Province, China [6]Institute of General Surgery, Jinling Hospital, Nanjing 210002, Jiangsu Province, China [7]Institute of Laboratory Medicine, Jinling Hospital, Nanjing 210002, Jiangsu Province, China [8]Department of Environmental Toxicology, The Institute of Environmental and Human Health, Texas Tech University, Lubbock TX 79409, United States

出　　处：《World Journal of Gastroenterology》2008年第19期3074-3080,共7页世界胃肠病学杂志（英文版）

摘　　要：AIM：To evaluate the diagnostic role of serum RASSF1A promoter hypermethylation in gastric and colorectal adenocarcinoma. METHODS：Methylation-specific polymerase chain reaction （MSPCR） was used to examine the promoter methylation status of the serum RASSF1A gene in 47 gastric adenocarcinoma patients, 45 colorectal adenocarcinoma patients, 60 patients with benign gastrointestinal disease （30 with benign gastric disease and 30 with benign colorectal disease）, and 30 healthy donor controls. Apaired study of RASSF1A promoter methylation status in primary tumor, adjacent normal tissue, and postopertive serum were conducted in 25 gastric and colorectal adenocarcinoma patients who later were underwent surgical therapy. RESULTS：The frequencies of detection of serum RASSF1A promoter hypermethylation in gastric （34.0%） and colorectal （28.9%） adenocarcinoma patients were significantly higher than those in patients with benign gastric （3.3%） or colorectal （6.7%） disease or in healthy donors （0%） （P 〈 0.01）. The methylation status of RASSF1A promoter in serum samples was consistent with that in paired primary tumors, and the MSPCR results for RASSF1A promoter methylation status in paired preoperative samples were consistent with those in postoperative serum samples. The serum RASSF1A promoter hypermethylation did not correlate with patient sex, age, tumor differentiation grade, surgical therapy, or serum carcinoembryonic antigen level. Although the serum RASSF1A promoter hypermethylation frequency tended to be higher in patients with distant metastases, there was no correlation between methylation status and metastasis. CONCLUSION：Aberrant CpG island methylation within the promoter region of RASSF1A is a promising biomarker for gastric and colorectal cancer.AIM:To evaluate the diagnostic role of serum RASSF1A promoter hypermethylation in gastric and colorectal ad- enocarcinoma. METHODS:Methylation-specific polymerase chain reac- tion (MSPCR) was used to examine the promoter meth- ylation status of the serum RASSF1A gene in 47 gastric adenocarcinoma patients, 45 colorectal adenocarcinoma patients, 60 patients with benign gastrointestinal dis- ease (30 with benign gastric disease and 30 with benign colorectal disease), and 30 healthy donor controls. Apaired study of RASSF1A promoter methylation status in primary tumor, adjacent normal tissue, and postopera- tive serum were conducted in 25 gastric and colorectal adenocarcinoma patients who later were underwent sur- gical therapy. RESULTS:The frequencies of detection of serum RASSF1A promoter hypermethylation in gastric (34.0%) and colorectal (28.9%) adenocarcinoma patients were significantly higher than those in patients with benign gastric (3.3%) or colorectal (6.7%) disease or in healthy donors (0%) (P < 0.01). The methylation status of RASSF1A promoter in serum samples was consistent with that in paired primary tumors, and the MSPCR results for RASSF1A promoter methylation status in paired preoperative samples were consistent with those in postoperative serum samples. The serum RASSF1A promoter hypermethylation did not correlate with patient sex, age, tumor differentiation grade, surgical therapy, or serum carcinoembryonic antigen level. Although the serum RASSF1A promoter hypermethylation frequency tended to be higher in patients with distant metastases, there was no correlation between methylation status and metastasis. CONCLUSION:Aberrant CpG island methylation within the promoter region of RASSF1A is a promising biomark- er for gastric and colorectal cancer.

关 键 词：Gastric cancer Colorectal cancer Genemethylation RASSFIA 

分 类 号：R735.3[医药卫生—肿瘤]